[Proserotoninergic agents and depression (author's transl)].
The proserotoninergic hypothesis of depression has been for a long time founded on biochemical parameters (brain from suicide patients, CSF and plasma from depressed patients) or more recently on measurement of platelets 5-HT uptake or imipramine binding. New specific proserotoninergic agents confirm this hypothesis since indalpine, a specific 5-HT uptake inhibitor, has a neurochemical and pharmacological profile characteristics of proserotoninergic agents and is effectively antidepressant in human. 5-HT uptake inhibition seems an important property because when we compared two isomers one, a 5-HT uptake inhibitor and at the same time 5-HT releaser, and the other only releaser, we observed that the first has experimental properties similar to indalpine whereas the second has not the classical spectrum of a proserotoninergic agent.
D000818:Animals; D001921:Brain / Q000378:metabolism; D003866:Depressive Disorder / Q000188:drug therapy* / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D009638:Norepinephrine / Q000378:metabolism; D010880:Piperidines / Q000627:therapeutic use; D011985:Receptors, Serotonin / Q000187:drug effects*; D012701:Serotonin / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000627:therapeutic use; D009435:Synaptic Transmission / Q000187:drug effects
D010880:Piperidines; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D012701:Serotonin; C018181:indalpine; D004298:Dopamine; D009638:Norepinephrine
Agents prosérotoninergiques et dépression.